| Online-Ressource |
Verfasst von: | Schulze-Koops, Hendrik [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Skapenko, Alla [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Krause, Andreas [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Krueger, Klaus [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Lorenz, Hanns-Martin [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Sewerin, Philipp [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Specker, Christof [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Wagner, Ulf G. [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Voormann, Anna [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Müller-Ladner, Ulf [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
| Voll, Reinhard [VerfasserIn] ![i](/https/katalog.ub.uni-heidelberg.de/opacicon/information2.png) |
Titel: | Correspondence to ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’ |
Verf.angabe: | Hendrik Schulze-Koops, Alla Skapenko, Andreas Krause, Klaus Krueger, Hanns-Martin Lorenz, Philipp Sewerin, Christof Specker, Ulf G. Wagner, Anna Voormann, Ulf Mueller-Ladner, Reinhard E. Voll |
Jahr: | 2023 |
Umfang: | 1 S. |
Fussnoten: | Online veröffentlicht: 30. Oktober 2020 ; Gesehen am 19.12.2023 |
Titel Quelle: | Enthalten in: Annals of the rheumatic diseases |
Ort Quelle: | London : BMJ Publ. Group, 1939 |
Jahr Quelle: | 2023 |
Band/Heft Quelle: | 82(2023), 1, Artikel-ID e1 |
ISSN Quelle: | 1468-2060 |
Abstract: | The significance of inflammatory rheumatic diseases (IRDs) and their therapies for the risk of patients with respect to SARS-CoV-2 infection and the course of COVID-19 is still not fully understood. In particular, it is not completely clear whether IRDs, their therapies or other factors in patients with IRDs pose a risk to patients and what consequences should be drawn to protect patients with IRDs. In their manuscript, Nuñez et al 1 describe that in a real-world-setting SARS-CoV-2-infected patients with IRDs often require hospitalisation. Important in their observation is that this was associated with systemic autoimmune conditions (as opposed to well-controlled chronic inflammatory arthritis) and related to risk factors known also for the non-rheumatic population, such as advanced age or comorbidities, but not with the immunomodulating, antirheumatic therapy. - - These data are reassuring, as they underline once again that well-controlled IRDs per se do not pose a risk of contracting SARS-CoV-2 nor do ongoing immunomodulating therapies pose a threat for patients with IRD.2-5 Therefore, in order to avoid reactivation of an underlying IRD and to prevent the risk of increased susceptibility to infection and a possibly necessary administration of glucocorticoids to control immunological activity, several professional societies have advocated in their recommendations for the management of patients with IRDs in times of SARS-CoV-2/COVID-19 the continuation of therapy with anti-inflammatory drugs, provided that clinical symptoms of COVID-19 do not develop.6-8 On the other hand, these guidelines also recommend strict adherence to the hygiene and distance measures to reduce the risk of exposure to the virus. In this respect, several recent comparative surveys of patients with IRDs and the non-rheumatic population have shown that patients with IRDs do not actually have a different risk of infection than the general … |
DOI: | doi:10.1136/annrheumdis-2020-218997 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1136/annrheumdis-2020-218997 |
| Volltext: https://ard.bmj.com/content/82/1/e1 |
| DOI: https://doi.org/10.1136/annrheumdis-2020-218997 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | autoimmune diseases |
| cytokines |
| inflammation |
K10plus-PPN: | 187639000X |
Verknüpfungen: | → Zeitschrift |
Correspondence to ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’ / Schulze-Koops, Hendrik [VerfasserIn]; 2023 (Online-Ressource)